Josep M. Llovet, MD, PhD

Articles

Dr. Llovet on Considering Safety Profiles During Treatment Selection in HCC

September 7th 2021

Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.

Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC

August 6th 2019

Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.

Dr. Llovet on REACH Trials With Ramucirumab in HCC

July 17th 2019

Josep M. Llovet, MD, PhD, discusses the REACH and REACH-2 trials, which examined ramucirumab versus placebo in sorafenib-intolerant patients with hepatocellular carcinoma and elevated baseline alpha fetoprotein.

Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC

January 19th 2019

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

Dr. Llovet on Precision Medicine in HCC

October 19th 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.

Dr. Llovet on Combination Therapy in HCC

September 26th 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.

Dr. Llovet on Biomarkers for HCC

September 15th 2018

Josep M. Llovet, MD, PhD, Icahn School of Medicine, discusses the potential for biomarkers to improve the treatment of hepatocellular carcinoma (HCC).